Cargando…

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies

Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Melissa T., Yuan, Long, Klee, Alyssa N., Freeman, Gordon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/
https://www.ncbi.nlm.nih.gov/pubmed/35925787
http://dx.doi.org/10.1089/mab.2021.0068
_version_ 1784784675403726848
author Bu, Melissa T.
Yuan, Long
Klee, Alyssa N.
Freeman, Gordon J.
author_facet Bu, Melissa T.
Yuan, Long
Klee, Alyssa N.
Freeman, Gordon J.
author_sort Bu, Melissa T.
collection PubMed
description Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents.
format Online
Article
Text
id pubmed-9451140
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-94511402022-09-08 A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies Bu, Melissa T. Yuan, Long Klee, Alyssa N. Freeman, Gordon J. Monoclon Antib Immunodiagn Immunother Short Communications Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents. Mary Ann Liebert, Inc., publishers 2022-08-01 2022-08-25 /pmc/articles/PMC9451140/ /pubmed/35925787 http://dx.doi.org/10.1089/mab.2021.0068 Text en © Melissa T. Bu et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by-nc/4.0/This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
spellingShingle Short Communications
Bu, Melissa T.
Yuan, Long
Klee, Alyssa N.
Freeman, Gordon J.
A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title_full A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title_fullStr A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title_full_unstemmed A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title_short A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
title_sort comparison of murine pd-1 and pd-l1 monoclonal antibodies
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451140/
https://www.ncbi.nlm.nih.gov/pubmed/35925787
http://dx.doi.org/10.1089/mab.2021.0068
work_keys_str_mv AT bumelissat acomparisonofmurinepd1andpdl1monoclonalantibodies
AT yuanlong acomparisonofmurinepd1andpdl1monoclonalantibodies
AT kleealyssan acomparisonofmurinepd1andpdl1monoclonalantibodies
AT freemangordonj acomparisonofmurinepd1andpdl1monoclonalantibodies
AT bumelissat comparisonofmurinepd1andpdl1monoclonalantibodies
AT yuanlong comparisonofmurinepd1andpdl1monoclonalantibodies
AT kleealyssan comparisonofmurinepd1andpdl1monoclonalantibodies
AT freemangordonj comparisonofmurinepd1andpdl1monoclonalantibodies